TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway
Biochemistry and Cell Biology · 2025
DOI: 10.1139/bcb-2025-0034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemistry and Cell Biology, 2025. Verfasst von Liang Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Second People's Hospital of Jingdezhen, Jingdezhen, Jiangxi Province 333000, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Education Department of Jiangxi Province.
Abstract (Originalsprache)
Ovarian cancer is one of the most common and lethal malignancy tumors in women. Chemoresistance is one of the main reasons for ovarian cancer relapsing. Understanding the regulatory mechanisms of chemoresistance generation is critical to develop novel therapeutic strategies. Here, we found that TRIM46 was upregulated in ovarian cancer cells and tissues with chemoresistance and associated with poor outcomes. Functional assays showed that TRIM46 promoted cisplatin (CDDP) chemoresistance. Furthermore, TRIM46 interacts with PI3K/AKT pathway inactivator pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2) and downregulated PHLPP2 level. Treating with PI3K/AKT pathway inhibitor significantly reversed the effects of TRIM46-overexpressing on chemoresistance. In summary, our study reveals that TRIM46 promoted chemoresistance via downregulating PHLPP2, leading to activating PI3K/AKT pathway. This study provides a novel potential target for ovarian cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, The Second People's Hospital of Jingdezhen, Jingdezhen, Jiangxi Province 333000, China.
- Department of General Surgery, Hui Ya Hospital of The First Affiliated Hospital of Sun Yat-sen University, Huizhou, Guangdong, 516081, China.
- Department of Gynecology and Obstetrics, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province 341000, China.
- Department of Neurology, Hui Ya Hospital of The First Affiliated Hospital of Sun Yat-sen University, Huizhou, Guangdong, 516081, China.
- Department of Ultrasound medicine, the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province 341000, China.
ORCID-Profile: Liang Peng
Förderung
- Education Department of Jiangxi Province
Zitieren
APA
Peng, L., Liu, L., Xu, L., Chen, J., Wang, X., Zhang, M., & Ge, Y. (2025). TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2025-0034
Vancouver
Peng L, Liu L, Xu L, Chen J, Wang X, Zhang M, et al. TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway. Biochemistry and Cell Biology. 2025. doi:10.1139/bcb-2025-0034
BibTeX
@article{Peng2025,
author = {Peng, Liang and Liu, Limei and Xu, Ling and Chen, Jie and Wang, Xiaohui and Zhang, Meihua and Ge, Yilong},
title = {TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway},
journal = {Biochemistry and Cell Biology},
year = {2025},
doi = {10.1139/bcb-2025-0034}
}
EUVIMED